Creo Medical Group PLC (LON:CREO - Get Free Report)'s stock price traded up 2.6% on Tuesday . The stock traded as high as GBX 19.50 ($0.25) and last traded at GBX 19.50 ($0.25). 149,612 shares were traded during trading, a decline of 75% from the average session volume of 598,117 shares. The stock had previously closed at GBX 19 ($0.24).
Creo Medical Group Stock Performance
The company has a market capitalization of £76.81 million, a P/E ratio of -3.01 and a beta of 0.86. The company has a debt-to-equity ratio of 29.96, a current ratio of 3.24 and a quick ratio of 2.19. The company has a fifty day moving average price of GBX 18.39 and a two-hundred day moving average price of GBX 21.92.
Insider Buying and Selling
In other Creo Medical Group news, insider Christopher Paul Hancock purchased 4,712 shares of the company's stock in a transaction on Monday, January 20th. The shares were purchased at an average cost of GBX 19 ($0.24) per share, with a total value of £895.28 ($1,126.85). Also, insider Kevin Crofton bought 1,179,000 shares of the stock in a transaction dated Friday, December 13th. The shares were purchased at an average cost of GBX 17 ($0.21) per share, for a total transaction of £200,430 ($252,271.87). Insiders have purchased a total of 1,188,424 shares of company stock valued at $20,222,056 over the last ninety days. 22.43% of the stock is owned by company insiders.
Creo Medical Group Company Profile
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Read More
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
